Caplin Steriles gets USFDA okay for generic Argatroban Injection

Chennai: Drugmaker, Caplin Point Laboratories Limited has recently announced that the company's subsidiary Caplin Steriles Limited has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Argatroban Injection, 50 mg/50 ml (1 mg/ml) Single-dose vial presentation,

The product is a generic therapeutic equivalent version of (RLD), ARGATROBAN INJECTION, of Hikma Pharmaceuticals Limited.

Caplin has received a CGT (Competitive Generic Therapies) Grant for this ANDA and Caplin is the "first approved applicant" for such competitive generic therapy, as defined in section 505(j)(5)(B)(v)(III) of the FD&C Act. Therefore, with this approval, Caplin is eligible for 180 days of CGT exclusivity for Argatroban Injection, 50 mg/50 ml (1 mg/ml) Single- Dose Vial, under section 505(j)(5)(B)(v) of the FD&C Act.

Argatroban is used as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.

According to IQVIA™ {IMS Health), Argatroban Injection had US sales data of approximately $18 million for the 12-month period ending Sep 2020.

Mr. C. C. Paarthipan, Chairman of Caplin Point Laboratories Limited commented "We're excited to receive our first approval with CGT exclusivity from our pipeline. We will target launching the product within the shortest time possible."